Dylan Zylla is a Research investigator and Medical oncologist and hematologist and co-medical director for oncology research. Dr. Dylan Zylla has completed MD, University of Minnesota Medical School; residency (internal medicine), University of Minnesota; chief residency, University of Minnesota (VA Hospital); fellowship (hematology/oncology), University of Minnesota; masters in clinical research, University of Minnesota (anticipated).In addition to his investigator-initiated research, Dr. Zylla is the principal investigator on numerous pharmaceutical clinical trials at Park Nicollet. Recently, he led a study assessing the impact of a synthetic cannabis product (Sativex) and continues to explore new ways to study the risks and benefits of medical cannabis through the Minnesota Medical Cannabis Program. Through his work with the Metro-Minnesota Community Oncology Research Consortium, he had the highest accrual of cancer patients in clinical trials in the Twin Cities in 2014. Dr. Zylla was also awarded the 2016 Association of Community Cancer Centers Innovation Award for "Establishing Personalized Pain Goals in Oncology Patients to Improve Care and Decrease Costs."

Dr. Zylla's research focuses on how cancer pain and opioid utilization may impact survival in patients with advanced cancers. He leads projects focused on improving cancer pain and symptom management at Park Nicollet and collaborated with the American Society of Clinical Oncology on a project to improve the integration of palliative care into oncology practices. Dr. Zylla also serves on the Minnesota Community Measurement’s workgroup that develops quality measures for cancer symptom control using patient-reported outcomes.